WHO's antibacterial pipeline reports

Despite this attention from WHO, global pharmaceutical companies focusing on antibiotic development have given up their treasure hunt for new candidates, returning to antimicrobials only because of COVID-19. To Noonan, there are two sub-factors: the timing between medicine administration and cure, and the cost of production versus sale. For more on the AMR Action Fund see https://www.amractionfund.com/ For the WHO priority pathogens list see https://www.who.int/news/item/27-02-2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed For WHO's antibacterial pipeline report see https://www.who.int/publications/i/item/9789240047655 For WHO's bacterial vaccine pipeline report see https://www.who.int/publications/i/item/9789240052451